Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate-specific antigen level: Is there a difference?

BJU International

Volumn 101, Issue 7, 2008, Pages 822-825

  Pelzer, Alexandre E ^a,d   Colleselli, Daniela ^a   Bektic, Jasmin ^a   Steiner, Eberhard ^a   Ramoner, Reinhold ^a   Mitterberger, Michael ^a   Schwentner, Christian ^a   Schaefer, Georg ^b   Ongarello, Stefano ^c   Bartsch, Georg ^a   Horninger, Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Gleason score; Prostate cancer; PSA; Recurrence; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SCREENING; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATECTOMY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 40449128934     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07454.x     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007 51 : 1175 84
3. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000 164 : 101 5
4. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 2002 167 : 528 34
5. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005 294 : 433 9
6. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001 165 : 119 25
7. Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001 58 : 417 24
8. Oesterling JE, Kumamoto Y, Tsukamoto T et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 1995 75 : 347 53
9. Pelzer A, Bektic J, Berger AP et al. Prostate cancer detection in men with prostate specific antigen 4-10 ng/mL using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 2005 173 : 1926 9
10. Walsh PC. Nerve sparing radical prostatectomy for early stage prostate cancer. Semin Oncol 1988 15 : 351 8
11. Aus G, Abbou CC, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2005 48 : 546 51
12. Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology 2005 66 : 156 60
13. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994 152 : 1837 42
14. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 7
15. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006 98 : 355 7
16. Klotz LH, Nam RK. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis. Can J Urol 2006 13 (Suppl. 1 48 55
17. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004 171 : 1520 4
18. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001 28 : 555 65
19. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update. J Urol 1994 152 : 1358 68
20. Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 2002 53 : 297 303